SecBot SecBot
8-K ·Filed Jul 13, 2026

TCMD

TACTILE SYSTEMS TECHNOLOGY INC
BULLISH
Impact 5/10
Horizonmonths Processed4mo ago SEC0001104659-26-082947
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

This is a modest portfolio expansion into a new patient segment (earlier-stage chronic swelling) via a VA/DoD-exclusive channel. The $3M upfront is small relative to the $673M market cap. Monitor for initial sales traction and reimbursement progress in the VA/DoD system over the next 2-3 quarters.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$29.04
T+0 close · Jul 13, 2026 · via day close
Latest settled
−23.59%
T+60 · $22.19
Vs SPY
−27.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $29.04entry
  2. T+1 · 4mo ago −4.89%α −5.24% · $27.62
  3. T+5 · 4mo ago −1.03%α −0.25% · $28.74
  4. T+20 · 3mo ago +0.34%α −2.84% · $29.14
  5. T+60 · 6w ago −23.59%α −27.58% · $22.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tactile Medical announced an exclusive U.S. distribution agreement with ElastiMed for MyoSleeve, a wearable non-pneumatic compression device, targeting VA and DoD patients. The company made a $3 million upfront payment and committed to minimum purchase obligations, expanding its chronic swelling portfolio into earlier-stage disease.

Key Facts

  • Exclusive U.S. distribution rights for MyoSleeve within VA and DoD systems
  • Upfront payment of $3 million to ElastiMed
  • MyoSleeve is FDA 510(k) cleared for chronic swelling, lymphedema, and venous insufficiency
  • Device uses electroactive polymer technology, is battery-powered, and operates without tubing or external controller
  • Expands Tactile Medical's portfolio into earlier stages of chronic swelling, complementing existing pneumatic compression devices

Financial Impact

$3 million upfront payment plus undisclosed minimum purchase obligations and marketing commitments

revenueoperating expenses

Risk Factors

  • Minimum purchase obligations could pressure cash flow if adoption is slow
  • VA/DoD sales cycles are long and unpredictable
  • MyoSleeve is a complementary product, not a replacement for core pneumatic devices, revenue contribution may be limited

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-082947
Document: tm2620304d1_ex99-1.htm0001104659-26-082947
Document: 0001104659-26-082947-index-headers.html0001104659-26-082947
Document: 0001104659-26-082947-index.html0001104659-26-082947
Document: 0001104659-26-082947.txt0001104659-26-082947

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026